pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›calendar
  3. ›phase readout
phase readout
save

NCT06778863: A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

RECRUITING$CCCCupdated 5mo ago
community read0 votes

Sponsor: Clasp Therapeutics, Inc.. Phase: PHASE1. Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Bladder Cancer

view source ↗
Data sources
ctgov
last refreshed 3h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

same company · ±60 days · 2

  • approvalcosibelimab: UNLOXCYT (COSIBELIMAB-IPDL) — FDA approvalNov 21, 2025
  • approvalcosibelimab: UNLOXCYT (COSIBELIMAB-IPDL) — FDA approvalDec 13, 2024

related news · 2

  • biospaceGenentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio↗
  • fiercebiotechBiotech industry leaders file brief backing FDA against ‘malicious’ mifepristone challenge↗

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?